THE AMINO ACID SEQUENCE OF HYPERTENSIN II by Skeggs, Leonard T. et al.
THE  AMINO ACID  SEQUENCE  OF  HYPERTENSIN  II 
BY LEONARD T. SKEGGS, JR., PH.D., KENNETH E. LENTZ, PH.D., 
JOSEPH R. KAHN, M.D., NORMAN P.  SHUMWAY, M.D., ~'D 
KENNETH R. WOODS, I~.D. 
(From the Department of Medicine and Surgery, Veterans Administration 
Hospital, and the Department of Pathology, Western Reserve 
University, Cleveland) 
(Received for publication, May 3, 1956) 
The pressor substance hypertensin, which has been found in the blood of 
many human beings with hypertensive cardiovascular disease (1), as well as 
in animals with experimental renal hypertension (2),  may actually exist in 
two forms (3). The first form, hypertensin I, is the initial product of the action 
of the renal enzyme renin upon its plasma substrate and is not a  vasocon- 
strictor or a directly pressor substance. It may be rapidly changed to the second 
form, hypertensin II, by a chloride-activated converting enzyme contained in 
the plasma. Hypertensin II is an extremely powerful vasoconstrictor material 
and is therefore the effector substance of the renin-hypertensin system (4, 5). 
Hypertensin I  has been isolated from horse blood in a highly purified form 
(6). This material was treated with partially purified converting enzyme (4, 7) 
and  after  countercurrent  distribution  of  the  products,  homogenous hyper- 
tensin II as well as a biologically inactive peptide residue was obtained. Quan- 
titative amino acid analysis (8, 9) of these three substances together with the 
use of the enzyme carboxypeptidase (9) allowed the conversion to be expressed 
as a  balanced biochemical equation. 
Hypertensin I  converting  enzyme  hypertensin II +  dipeptide 
(asp-arg-val-tyr-iso-hist  -pro) -phe-hist-leu  converting  enzyme 
(asp-arg-vaJ-tyr-iso-hist-pro)-phe +  hist-leu 
It is the purpose of this paper to report the amino acid sequence of hyper- 
tensin II as determined by the use of chymotrypsin, the fluorodinitrobenzene 
method, and stepwise phenylisothiocyanate degradation. 
EXPERIMENTAL 
Treatment  of Hypertensin II with Chymotrypsin.--Chymotrypsin  is known 
to  hydrolyze peptide bonds  which  involve the  carboxyl group  of aromatic 
amino acids (10).  Inasmuch as hypertensin II has only one such group it was 
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expected that this enzyme would divide the molecule into two fragments each 
of which might be amenable to further analysis. 
A solution of hypertensin II containing 4.1 mg. of N and a minimum  d  44,000 Goldblatt 
units (11) was treated with 0.5 rag. of a commercial preparation of crystalline chymotryp- 
sin. The reaction mixture with a volume of 50 ml. was allowed to remain at room tempera- 
ture and was maintained at pH 7.7 by occasional additions of 0.1 ~ NaOH. Small aliquots 
were  withdrawn at suitable intervals and after inactivation of the enzyme  by heat were 
diluted and assayed for pressor activity in the rat  (12). After 37 minutes all but 50 units 
had been destroyed and the reaction was terminated by raising the temperature to 100°C. 
for 20 minutes.  After cooling, the material was loaded in the first two tubes of a 200 tube 
Craig-Post countercurrent distribution apparatus  (13). The machine  was  operated for  71 
transfers using the solvent system n-butanol-water. Ninhydrin analyses (14) of the aqueous 
layer showed the presence of two components;  peptide A and peptide B. The distribution 
coefficients of these two substances  were 0.06 and 0.67 respectively.  Mter pooling the solu- 
tions from  the  appropriate tubes were  evaporated to  convenient  volumes  and  saved for 
further  analysis.  Descending  paper  chromatograms were  obtained  on  both  fractions  by 
using a n-butanol-water-acetic acid (4:1:5)  solvent system.  Peptide A gave a  single nin- 
hydrin positive spot with an R! of 0.38. Peptide B also gave a single ninhydrin spot with an 
R  s of 0.63. This spot stained with Durrum's reagent.  The ultraviolet spectrum of peptide A 
was  determined and  found  to  correspond  closely  to  that  of tyrosine.  Calculations  based 
upon the molar extinction coefficient at 274.5 m/z showed the presence of 30.2 #~r. The ab- 
sorption of peptide B was small and not characteristic of tyrosine. 
Aliquots of both peptides amounting to 8.0/z~, as determined by the ninhydrin method, 
were  hydrolyzed under reflux for 24 hours in constant boiling  HC1. These  samples  were 
subjected to quantitative chromatography upon 100 cm. dowex 50 X  8 columns  according 
to the methods of Stein and Moore (15). The results obtained revealed that peptide A was 
composed of aspartic acid, arginine,  valine,  and  tyrosine in approximately whole  number 
molar ratios.  Peptide B contained  isoleucine, histidine, proline, and phenylalanine,  also  in 
nearly equimolar amounts. 
It appeared from the foregoing experiments that chymotrypsin hydrolyzed 
a  single peptide bond in  the hypertensin  II molecule yielding two  peptides. 
These may be written as: 
Peptide A  Peptide B 
(asp-arg-val-tyr)  q-  (iso-hist-pro)-phe 
The position of phenylalanine at the C  terminal of peptide B  was known from 
previous experiments in which it was demonstrated  that phenyIalanine is re- 
leased from the C  terminal of hypertensin II by the action of carboxypeptidase 
(9).  The presence of proline adjoining phenylalanine was  suspected from  the 
known inability of carboxypeptidase to remove terminal proline from peptide 
chains (16). The C terminal position of tyrosine in peptide A was also indicated 
from  the  known  specificity of  chymotrypsin. 
The Amino Acid Sequence of Peptide B.--The N  terminal stepwise degrada- 
tion of 4.5 u~ of peptide B  was then performed using the phenylisothiocyanate 
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The phenylthiohydantoin  derivatives of isoleucine, histidine, and proline were each re- 
moved in turn from the peptide  and identified by direct paper  chromatography.  No diffi- 
culty was experienced except in the case of the third step when it proved necessary to heat 
the prolyl phenylalanine peptide derivative to 50°C. in the presence of 3N HCI in order to 
remove the phenylthiohydantoin derivative of proline. 
Additional confirmation of the progress of the degradation was obtained by hydrolysis 
and paper  chromatography  of the peptide  fraction  remaining after  the  removal  of each 
N  terminal amino acid  derivative.  The results of the  chromatograms  thus  secured were 
consistent with the aforementioned N terminal sequence. The final peptide fraction remain- 
ing after these degradation steps was found to contain free phenylalanine. 
As a result of these studies it was then possible to assign the following partial 
amino acid sequence  :-- 
(asp-arg-val-tyr)  -iso-hist-pro-phe 
The N  Terminal Sequence of Hypertensin I  and Hypertensin //.--Application 
of the fluorodinitrobenzene  technique of Sanger (18), as modified by Fraenkel- 
Conrat eta/. (17) to a  1.0 ;~ sample of hypertensin II revealed the N  terminal 
amino acid to  be  asparfic  acid.  Similar results  were  obtained with  a  small 
sample of hypertensin I. 
Owing to the ready  availability  of hypertensin  I  this  compound was used for further 
determinations. A 20 ;zm sample of hypertensin I  was subjected to one cycle of phenyliso- 
thiocyanate degradation. The phenylthiohydantoin  derivative of aspartic acid thus obtained 
was identified as the free amino acid by paper  chromatography  following hydrolysis. An 
aliquot  of the remaining peptide  fraction was then treated  with  fluorodinitrobenzene and 
after hydrolysis and chromatography the dinitrophenyl derivative of arginine was identified. 
The peptide fraction minus aspartic  acid was again treated  with phenylisothiocyanate. In 
this case the amino acid derivative released could not be separated  from the peptide  frac- 
tion. This is consistent with the behavior of the phenylthiohydantoin derivative of arginine, 
The peptide fraction, now minus aspartic acid and arginine was then treated  for the third 
time with  the  phenylisothiocyanate  method  yielding a  phenylthiohydantoin  amino  acid 
which was identified after hydrolysis as valine. This finding was confirmed by application 
of the fluorodinitrobenzene technique. 
The fourth  step  in the  phenylisothiocyanate degradation of  this  material 
was  unsuccessful and yielded equivocal  results.  Additional  direct  evidence 
as to the position of tyrosine in the molecule was obtained in a partially sucess- 
ful acid degradation experiment. 
A sample of carboxypeptidase treated  hypertensin  I  containing all of the amino acids 
of hypertensin II except the C terminal phenylalanine was heated at 100°C. for 3 hours in 
the presence of 3 N HC1. Among the reaction products the tripeptide arginyl-valyl-tyrosine 
was isolated by dowex 50 :K 2 chromatography and its sequence determined by the phenyl- 
isothiocyanate method. 
It was therefore possible to establish the amino acid sequence of hypertensin 
II as follows:-- 
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DISCUSSION 
The purification  of a pressor  peptide derived  from ox serum has recently 
been described by Peart (19). This material was not identified as being either 
hypertensin I  or hypertensin II, nor have the experimental  procedures  been 
described  in enough  detail to allow an identification.  In a  still  more recent 
communication  Elliott and Peart (20) report an amino acid sequence for this 
material which corresponds to that of horse hypertensin I with the exception 
that valine is  substituted for isoleucine. 
It is of paramount interest to discover  a  therapeutic method of lowering 
the blood pressure of human beings afflicted with hypertensive cardiovascular 
disease. Owing to  the knowledge now available  concerning  the structure of 
hypertensin I, hypertensin II, and the converting enzyme it becomes possible 
for  the first  time  to  approach  this problem  upon  rational grounds.  Three 
separate avenues  of attack appear to be feasible. It may now be possible to 
discover and protect by structural analogs  the bond which the enzyme renin 
dissociates when hypertensin I  is formed from renin substrate. It is possible 
that the C terminal leucine of hypertensin I is involved in this bond since the 
converting enzyme does not release histidylleucine from the renin substrate. 
Highly purified renin is now available for this study, owing to the work  of 
Haas, Lamfrom, and Goldblatt (21). 
It may also be possible  to prevent the formation of hypertensin II from 
hypertensin I by the converting enzyme, for example by providing a structural 
analog  of  the  phenylalanyl-histidylleucine bond  or  by  an  immunological 
approach  using the converting  enzyme in a  manner similar to that which is 
partially successful in the case  of renin. 
Finally, it might be possible to prevent the vasoconstrictive  action of hyper- 
tensin  II  upon  smooth muscle.  Although the nature of  this  mechanism is 
completely  unknown the action might be blocked by analogs based upon the 
structure of hypertensin II. 
SUMMARY 
The amino acid sequence of horse hypertensin II has been  determined by 
the  use  of  chymotrypsin, the  fluorodinitrobenzene  method,  and  stepwise 
phenylisothiocyanate degradation. The results  indicate that the amino acids 
of hypertensin II are arranged in the following order: asp-arg-val-tyr-iso-hist- 
pro-phe. 
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